Jane Street Group LLC grew its stake in shares of HUTCHMED (China) Limited (NASDAQ:HCM - Free Report) by 54.7% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 97,470 shares of the company's stock after acquiring an additional 34,473 shares during the period. Jane Street Group LLC owned about 0.06% of HUTCHMED worth $1,405,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Summit Trail Advisors LLC raised its position in shares of HUTCHMED by 14.4% in the fourth quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company's stock worth $189,000 after acquiring an additional 1,647 shares during the period. Crossmark Global Holdings Inc. grew its stake in HUTCHMED by 10.7% during the 4th quarter. Crossmark Global Holdings Inc. now owns 18,591 shares of the company's stock valued at $268,000 after acquiring an additional 1,799 shares in the last quarter. Barclays PLC grew its stake in HUTCHMED by 1,483.6% during the 4th quarter. Barclays PLC now owns 2,407 shares of the company's stock valued at $35,000 after acquiring an additional 2,255 shares in the last quarter. Blue Trust Inc. grew its stake in HUTCHMED by 99.9% during the 4th quarter. Blue Trust Inc. now owns 7,068 shares of the company's stock valued at $102,000 after acquiring an additional 3,532 shares in the last quarter. Finally, OLD Mission Capital LLC purchased a new stake in shares of HUTCHMED in the 4th quarter valued at approximately $230,000. Institutional investors own 8.82% of the company's stock.
HUTCHMED Trading Up 0.7%
Shares of NASDAQ:HCM opened at $13.48 on Tuesday. The firm's 50-day simple moving average is $14.43 and its 200-day simple moving average is $15.12. The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07. HUTCHMED has a fifty-two week low of $11.51 and a fifty-two week high of $21.50.
Analysts Set New Price Targets
Several brokerages have recently commented on HCM. HSBC lowered shares of HUTCHMED from a "buy" rating to a "hold" rating in a report on Tuesday, May 13th. StockNews.com lowered shares of HUTCHMED from a "buy" rating to a "hold" rating in a report on Tuesday, May 13th.
Read Our Latest Research Report on HCM
HUTCHMED Company Profile
(
Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
